Efficacy Of Long-Term Cyclosporine Treatment Of Patients With Severe Dry Eye Disease Syndrome
Published 2024 - 42nd Congress of the ESCRS
Reference: PO876 | Type: Free paper | DOI: 10.82333/xssg-5s62
Authors: Ewa Mrukwa-Kominek* 1 , Martyna Nowak 2 , Monika Sarnat-Kucharczyk 1
1Dept of Ophthalmology,Silesian University of Medicine,Katowice,Poland;Dept of Ophthalmology,Prof. K. Gibinski University Clinical Center,Katowice,Poland, 2Ophthalmology,Centrum Medyczne Lux Med,Nowy Sącz,Poland
Purpose
The purpose of this study is to demonstrate, on the basis of studies, the effectiveness of cyclosporine administered in the form of the drug Ikervis. Cyclosporine administered on a long-term basis is effective in the treatment of patients with chronic severe disease, reducing the discomfort of praz improving their quality of life
Setting
Prof. K. Gibinski University Clinical Center of the Silesian Medical University in Katowice, Department of Ophthalmology
Methods
20 patients (40 eyes) with severe stage of DED, for whom previous treatment had been unsuccessful.The drug containing active ingredient cyclosporine (1mg/ml) was implemented, applied topically in the form of eye drops once a day. Before starting therapy, patients underwent the following tests: BCVA, Tbut, OSDI, Oxford fluorescein staining and Schirmer's test. The tests were then repeated after 1-3 months, 6, 12 and 24 months after lounching therapy. Based on the results collected, the effectiveness of the drug was compared and evaluated, as well as the rate of change noted between each tests.The results obtained between successive studies were subjected to statistical analysis
Results
Mean age was 53.5 years and 80% of them were women. Checking the OSDI results, there is clearly a very strong effect of cyclosporine treatment (p=0.002). The pre-treatment score was over 53 points, the final average score showed 35 points. The results of fluorescein ocular surface damage tests using the Oxford scale was improved significantly (p<0.05).
An average TBUT value of 5.95 sec before treatment changed to 6.45, 8.05, 8.95 and 9.90 sec after 4-12 weeks, 6, 12 and 24 months respectively.
TBUT assessing - Mauchly test results for the right eye: χ2(9) = 19.06; p = 0.025; for the left eye: χ2(9) = 18.23; p = 0.033
Conclusions
The results presented in the study allow us to draw the following conclusions:
1. Patients receiving therapy with the drug Ikervis experienced a great improvement in the symptoms present, and test results improved.
2. Cyclosporine treatment improves baseline markers (OSDI, TBUT, Schrimer’s test, Oxfords scale), but the best results can be observed 6- 12 months after the start of therapy